London--(Marketwire - September 24, 2007) -

               Curidium Medica plc ("Curidium" or the "Company")


                       -Presentation to be Webcast Live -

London, UK, 24 September 2007, Curidium Medica plc, (LSE: CUR) the personalized medicine company focused on bringing the right drug to the right patient, today announced that it will be presenting at the 2007 UBS Global Life Sciences Conferences in New York, New York, USA. Gosse B. Bruinsma, Executive Chairman, will be presenting the current status of the Company and its strategic business objectives. The presentation is scheduled at 1:00 pm local time on Thursday, 27 September 2007 in the Grand Hyatt Hotel. The presentation will be webcast and accessible remotely by persons wishing to follow the presentation live and will be archived for 30 days on the Company's website; for access please visit:

For further information, please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Anne Bruinvels +44 (0) 20 7554 8790
Chief Executive Officer, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/ bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.

2. Improved therapies identified through novel drug targets.

3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website:

Curidium Medica plc (c) 2002-2007. All rights reserved.
Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.
Email: Tel.: +44 (0)20 7554 8790, 
Fax: +44 (0)20 7554 8791

                      This information is provided by RNS
            The company news service from the London Stock Exchange